Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

De-ESCALaTE HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus-positive oropharyngeal squamous cell carcinoma.

Next Previous
X
Search
Trial Profile

De-ESCALaTE HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus-positive oropharyngeal squamous cell carcinoma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin
  • Indications Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms De-ESCALaTE; De-ESCALaTE-HPV

    • Most Recent Events

    • 01 Sep 2023 Results, as part of this study analyzing identify patients with low-risk HPVOPC at risk for recurrence by detection of HPV16 DNA in plasma and salivary rinses, published in the JAMA Otolaryngology-- Head and Neck Surgery
    • 04 May 2022 Results from two trials TROG 12.01 and De-ESCALaTE assessing the quantification of ITIC CD103 could be used to identify a population of HPV-associated OPSCC with superior prognosis published in the Annals of Oncology
    • 08 Jun 2021 Results assessing good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in two studies ( TROG 12.01 and De-ESCALaTE ) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top